Saluda Medical earned FDA approval for its biomarker-based automated patient programming platform used in spinal cord stimulation.
The platform, Eva, is compatible with all commercially implanted Evoke spinal cord stimulator systems, according to a Jan. 23 news release. Eva senses, measures and adjusts stimulation based on each patient's unique response.
"EVA has the potential to usher in new benefits for clinicians and staff with greater ease of use, faster and more consistent programming, and monitoring physiological data to adjust settings to an optimal therapeutic dose," Timothy Deer, MD, president and CEO of The Spine & Nerve Center of the Virginias in Charleston, W.Va, said in the release.